AREDS2 Clinical Trial Results Look Clear-until You Dig Deeper
- 01. AREDS2 Clinical Trial Results: The Clear Answer and the Hidden Nuance
- 02. Primary Trial Outcomes at a Glance
- 03. Why the Results Look Clear Until You Dig Deeper
- 04. Safety Findings That Changed Clinical Practice
- 05. Dietary Intake Subgroup: The 26% Risk Reduction Story
- 06. What the Trial Did NOT Find
- 07. Current Clinical Recommendations Based on AREDS2
- 08. Limitations and Unanswered Questions
- 09. Bottom Line for Patients and Clinicians
AREDS2 Clinical Trial Results: The Clear Answer and the Hidden Nuance
The AREDS2 clinical trial, published in JAMA on May 14, 2013, found that adding lutein (10mg) and zeaxanthin (2mg) to the original AREDS formulation reduced progression to advanced age-related macular degeneration (AMD) by 10% overall, with a 26% risk reduction for people in the lowest dietary intake quintile, while adding omega-3 fatty acids (DHA/EPA) showed no benefit. Crucially, removing beta-carotene from the formulation maintained efficacy while eliminating lung cancer risk for smokers, leading to the current recommended formula containing zinc (80mg), copper (2mg), vitamin E (400 IU), vitamin C (500mg), lutein (10mg), and zeaxanthin (2mg).
Primary Trial Outcomes at a Glance
The AREDS2 study enrolled 4,203 participants aged 50 to 85 across 82 clinical centers in the United States between 2006 and 2012, with mean participant age of 74 years and 57% female. The primary analysis showed the five-year probability of progression to advanced AMD ranged from 29% to 31% across all four study groups, with hazard ratio calculations revealing that none of the nutrient additions significantly affected progression in the primary randomisation.
| Intervention Tested | Risk Reduction for Advanced AMD | Statistical Significance |
|---|---|---|
| Lutein + Zeaxanthin (overall) | 10% | P=.04 |
| Lutein + Zeaxanthin (lowest dietary intake) | 26% | P=.01 |
| Omega-3 (DHA/EPA) | 0% | Not significant |
| No beta-carotene + Lutein/Zeaxanthin | 18% | P=.02 |
| Low zinc (25mg vs 80mg) | 0% | Not significant |
Why the Results Look Clear Until You Dig Deeper
The headline finding-that lutein/zeaxanthin provides modest benefit-mask critical subgroup nuances that fundamentally change clinical interpretation. Dr. Emily Y. Chew, MD, who reported the AREDS2 results at the 2013 ARVO annual meeting, explained that "because carotenoids can compete with each other for absorption in the body, beta-carotene may have masked the effect of the lutein and zeaxanthin in the overall analysis". This competition effect means the primary analysis underestimated L/Z benefits for millions of patients.
Post hoc subgroup analyses revealed that participants receiving L/Z and the AREDS formulation without beta-carotene experienced 18% reduction in AMD progression risk (P=.02) and 22% reduction for neovascular AMD specifically (P=.01) versus those treated with original AREDS formulation and no L/Z. The benefit was mostly for reducing risk of progression to neovascular AMD (11% risk reduction) with no significant impact on progression to central geographic atrophy.
Safety Findings That Changed Clinical Practice
A safety analysis including only non- and former smokers found an increased incidence of lung cancer development in the beta-carotene versus no beta-carotene group (2% vs 0.9%; P=.04), with more than 90% of cases occurring in former smokers. This finding drove the clear recommendation from AREDS2 for removing beta-carotene from supplements, as it did not contribute to efficacy while increasing lung cancer risk especially in people who smoke or previously smoked.
- Beta-carotene removal: Eliminated lung cancer risk without reducing protective effect against advanced AMD
- Zinc dose comparison: No difference between 80mg and 25mg zinc, though 25mg has not been compared to placebo
- GI side effects: Frequency of gastrointestinal disorders similar in low and high dose zinc groups, unlike original AREDS
- Mortality analysis: No statistically significant differences between primary randomisation groups in mortality or serious adverse events
Dietary Intake Subgroup: The 26% Risk Reduction Story
Pre-specified subgroup analyses stratifying patients by baseline dietary history found participants in the lowest quintile of lutein/zeaxanthin dietary intake had a 26% lower risk of AMD progression if treated with L/Z than if not (P=.01). This finding suggests that supplementation matters most for people whose diets lack green leafy vegetables, which are primary natural sources of these carotenoids.
The observational data suggested treatment with lutein/zeaxanthin might benefit lens opacity progression, though with about 75% of AREDS2 participants evaluable for cataract progression, L/Z supplementation had no statistically significant effect on primary endpoint of progression to cataract surgery. Secondary outcomes including development of any cataract, severe cataract, or 15-letter visual acuity loss also showed no significant benefit.
What the Trial Did NOT Find
Otherwise, main effects and other exploratory analyses found no treatment effects for adding DHA/EPA omega-3 fatty acids, lowering zinc dose, or removing beta-carotene alone (without L/Z replacement). The use of fish oil supplement could not be recommended based on these results, despite widespread consumer belief about omega-3 benefits for eye health.
The AREDS formulation had no effect on progression of lens opacities overall, and the trial did not find difference in effects between 80mg versus 25mg zinc regarding efficacy. The UK National Health Service suggests people may take lower zinc dose if higher dose upsets stomach, but 80mg remains the standard since 25mg level has not been compared to placebo as of 2020.
Current Clinical Recommendations Based on AREDS2
With about 75% of participants evaluable for cataract outcomes and primary analysis showing limited overall benefit, the AREDS study group recommended continued use of original AREDS formulation but with beta-carotene removed and replaced by lutein/zeaxanthin. This became the modern AREDS2 formula sold by major supplement manufacturers worldwide.
- Zinc: 80 mg as zinc oxide
- Copper: 2 mg as copper oxide (prevents zinc-induced anemia)
- Vitamin E: 400 IU
- Vitamin C: 500 mg
- Lutein: 10 mg
- Zeaxanthin: 2 mg
Limitations and Unanswered Questions
The overall evidence on beneficial and adverse effects from AREDS2 suggests lutein/zeaxanthin could be more appropriate than beta-carotene in AREDS-type supplements, but questions remain regarding whether findings are generalizable to the population as whole. Long-term safety profile of lutein/zeaxanthin supplementation beyond the five-year study period remains unclear, as does optimal dosing for different populations.
Studies in 2016 and 2018 later showed that the average 25% risk reduction from antioxidants and zinc varies by genotype, meaning genetic factors influence individual response to supplementation. The trial enrolled 97% white participants, limiting generalizability to other racial and ethnic groups with different AMD risk profiles.
Bottom Line for Patients and Clinicians
The AREDS2 clinical trial results look clear on surface-lutein/zeaxanthin helps, omega-3 doesn't, drop beta-carotene-until you dig deeper into subgroup effects and dietary interactions that dramatically modify outcomes. For the 26% of patients with lowest dietary lutein intake, supplementation provides substantial 26% risk reduction, while those with adequate dietary intake may see minimal benefit.
The evidence-based recommendation remains taking beta-carotene-free AREDS2 formula with lutein and zeaxanthin for high-risk AMD patients, while recognizing that individual response depends on baseline dietary intake, genetic factors, and smoking history. Regular monitoring by ophthalmologists remains essential since supplements slow but do not stop or reverse advanced AMD progression.
Everything you need to know about Areds2 Clinical Trial Results Look Clear Until You Dig Deeper
Who should take AREDS2 supplements?
People with intermediate-stage AMD bilaterally or intermediate AMD in one eye and advanced AMD in the fellow eye should take AREDS2 supplements, as these are the only groups shown to benefit from reduced progression to advanced AMD.
Should smokers take AREDS2 supplements?
Current smokers should avoid any formulation containing beta-carotene due to increased lung cancer risk, but can safely take the beta-carotene-free AREDS2 formula with lutein/zeaxanthin. Former smokers should also use beta-carotene-free formulations since 90% of lung cancer cases occurred in former smokers.
Does AREDS2 prevent cataracts?
No, the AREDS2 trial found no statistically significant effect on cataract progression or cataract surgery risk, despite observational data suggesting potential benefit from lutein/zeaxanthin. The supplements only reduced risk of progression to wet macular degeneration, not cataracts.
What is the difference between AREDS and AREDS2?
AREDS (published 2001) found original formulation reduced advanced AMD risk by 25%, while AREDS2 (published 2013) showed adding lutein/zeaxanthin and removing beta-carotene provided 18% additional reduction in specific subgroups without omega-3 benefit. AREDS2 also confirmed the original 25% risk reduction persisted at 10 years.
Are omega-3 fish oils recommended for AMD?
No, the AREDS2 trial did not find benefit from adding DHA/EPA omega-3 fatty acids (350mg DHA + 650mg EPA) to the AREDS formulation, and fish oil supplements could not be recommended based on these results. The primary analysis showed no significant impact on AMD progression from omega-3 addition.